USFDA Clears Strides’ Manufacturing Unit in Bengaluru

USFDA clears Strides’ manufacturing unit in Bengaluru

Strides' Bengaluru manufacturing unit receives USFDA clearance, ensuring compliance for international pharmaceutical markets.

Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility

Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.

Strides Pharma receives USFDA EIR for Bengaluru facility

Strides Pharma Science has announced that its flagship manufacturing facility in Bengaluru, India, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), indicating the closure of the inspection conducted at the facility. The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of the facility from May 12 to May 20, 2026. As previously disclosed to the stock exchang…